Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 16/20 | 0.68 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154365 | 0.94 | GSK3B (0.76) | GSK3BPBKNAMPT | |
| SCHEMBL4157424 | 0.90 | GSK3B (0.55) | GSK3BPBKNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4165115 | 0.88 | GSK3B (0.56) | GSK3BPBK | |
| SCHEMBL4161215 | 0.87 | GSK3B (0.60) | GSK3BPBKNAMPT | |
| SCHEMBL4144996 | 0.87 | GSK3B (0.58) | GSK3BPBKNAMPTNPC1RAB9A | |
| SCHEMBL4157394 | 0.86 | GSK3B (0.51) | GSK3BPBKNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4156465 | 0.85 | GSK3B (0.57) | GSK3BNPC1RAB9A | |
| SCHEMBL4164528 | 0.85 | GSK3B (0.56) | GSK3BNAMPTSMN1; SMN2 | |
| SCHEMBL4164546 | 0.85 | GSK3B (0.67) | GSK3BNAMPT | |
| SCHEMBL4164524 | 0.84 | GSK3B (0.61) | GSK3BPBKNAMPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | claimed |
| EP-1984370-A1 | IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Crystalgenomics, Inc. (KR) | 2008-10-29 | — | — | EP | claimed |
| WO-2007083978-A1 | IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-07-26 | — | — | WO | claimed |
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | disclosed |
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | disclosed |
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | GSK3B, GSK3A, MAP3K3 | GSK3B 1/4885PBK 999/4885NAMPT 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.